FDA sends warning letter to maker of Ozempic, Wegovy over unreported potential GLP-1 side effects

The FDA sent a warning letter this month to Novo Nordisk, alleging the drugmaker failed to report, in a timely manner, potential side effects in patients who took its popular medications containing semiglutide.